Menlo Therapeutics Inc. (MNLO) announced Sunday that its Phase 2 study of serlopitant, for the treatment of pruritus in adults and adolescents with a history of atopic dermatitis, did not meet its primary or key secondary efficacy endpoints.
from RTT - Before the Bell https://ift.tt/2v1Dz6r
via IFTTT
No comments:
Post a Comment